Highly efficient synthesis of [11C]PE2I, a selective radioligand for the quantification of the dopamine transporter using PET

被引:0
作者
Dolle, F
Bottlaender, M
Demphel, S
Emond, P
Fuseau, C
Coulon, C
Ottaviani, M
Valette, H
Loc'h, C
Halldin, C
Mauclaire, L
Guilloteau, D
Maziere, B
Crouzel, C
机构
[1] CEA, Dept Rech Med, Serv Hosp Frederic Joliot, F-91401 Orsay, France
[2] INSERM U316, Lab Biophys Med & Pharmaceut, F-37200 Tours, France
[3] CIS Bio Int, F-91192 Gif Sur Yvette, France
[4] Karolinska Hosp, Psychiat Sect, Dept Clin Neurosci, Karolinska Inst, S-17176 Stockholm, Sweden
关键词
PE2I; carbon-11; positron emission tomography; PET; dopamine transporter;
D O I
10.1002/1099-1344(200009)43:10<997::AID-JLCR385>3.3.CO;2-R
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
PE2I ((E)-N-(3-iodoprop-2-enyl)-2 beta-carbomethoxy-3 beta-(4'-tolyl) nortropane) is a cocaine derivative belonging to a new generation of selective dopamine transporter inhibitors. Labelled with iodine-123 (half-life : 13.1 hours), PE2I has been dedicated to the diagnostics of neurodegenerative diseases such as Parkinson's disease in humans using single photon emission computed tomography. Labelled with carbon-11 (half-life : 20.4 minutes), it can be used in the absolute quantification of the dopamine transporter (DAT) using the high-resolution, sensitive and non-invasive quantitative imaging technique PET (positron emission tomography). In this paper, the radiosynthesis of carbon-ii labelled PE2I was investigated and oriented towards the preparation of multi milliCuries of radiotracer. Typically, 200 to 300 mCi (7.4-11.1 GBq) of [C-11]PE2I were routinely obtained within 25 minutes of radiosynthesis (including HPLC purification) with specific radioactivities ranging from 0.8 to 1.2 Ci/mu mol (29.6-44.4 GBq/mu mol). Based on the preliminary PET experiments, it can be assumed that this radioligand would permit quantification of the DAT using PET and mathematical compartmental ligand-transporter models.
引用
收藏
页码:997 / 1004
页数:8
相关论文
共 50 条
  • [41] Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER
    Schou, M
    Halldin, C
    Sóvágó, J
    Pike, VW
    Gulyás, B
    Mozley, PD
    Johnson, DP
    Hall, H
    Innis, RB
    Farde, L
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2003, 30 (07) : 707 - 714
  • [42] PET examination of [11C]5-methyl-6-nitroquipazine, a radioligand for visualization of the serotonin transporter
    Sandell, J
    Halldin, C
    Sovago, J
    Chou, YH
    Gulyás, B
    Yu, MX
    Emond, P
    Någren, K
    Guilloteau, D
    Farde, L
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2002, 29 (06) : 651 - 656
  • [43] Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects
    Jyrki T. Kuikka
    Erkki Tupala
    Kim A. Bergström
    Jukka Hiltunen
    Jari Tiihonen
    [J]. European Journal of Nuclear Medicine, 1999, 26 : 1486 - 1488
  • [44] [11C]cyclopropyl-FLB 457:: A PET radioligand for low densities of dopamine D2 receptors
    Airaksinen, Anu J.
    Nag, Sangram
    Finnema, Sjoerd J.
    Mukherjee, Jogeshwar
    Chattopadhyay, Sankha
    Gulyas, Balazs
    Farde, Lars
    Halldin, Christer
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (13) : 6467 - 6473
  • [45] Regional dopamine synthesis in patients with schizophrenia using L-[β-11C]DOPA PET
    Nozaki, Shoko
    Kato, Motoichiro
    Takano, Harumasa
    Ito, Hiroshi
    Takahashi, Hidehiko
    Arakawa, Ryosuke
    Okumura, Masaki
    Fujimura, Yota
    Matsumoto, Ryohei
    Ota, Miho
    Takano, Akihiro
    Otsuka, Akihiko
    Yasuno, Fumihiko
    Okubo, Yoshiro
    Kashima, Haruo
    Suhara, Tetsuya
    [J]. SCHIZOPHRENIA RESEARCH, 2009, 108 (1-3) : 78 - 84
  • [46] Predictive value of dopamine transporter SPECT imaging with [123I]PE2I in patients with subtle parkinsonian symptoms
    Ziebell, Morten
    Andersen, Birgitte B.
    Thomsen, Gerda
    Pinborg, Lars H.
    Karlsborg, Merete
    Hasselbalch, Steen G.
    Knudsen, Gitte M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (02) : 242 - 250
  • [47] Age-related decline in dopamine transporter in human brain using PET with a new radioligand [18F]FE-PE2I
    Shingai, Yoshitoshi
    Tateno, Amane
    Arakawa, Ryosuke
    Sakayori, Takeshi
    Kim, WooChan
    Suzuki, Hidenori
    Okubo, Yoshiro
    [J]. ANNALS OF NUCLEAR MEDICINE, 2014, 28 (03) : 220 - 226
  • [48] Measurement error analysis for the determination of dopamine D2 receptor occupancy using the agonist radioligand [11C]MNPA
    Shidahara, Miho
    Ito, Hiroshi
    Otsuka, Tatsui
    Ikoma, Yoko
    Arakawa, Ryosuke
    Kodaka, Fumitoshi
    Seki, Chie
    Takano, Harumasa
    Takahashi, Hidehiko
    Turkheimer, Federico E.
    Kimura, Yuichi
    Kanno, Iwao
    Suhara, Tetsuya
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2010, 30 (01) : 187 - 195
  • [49] Predictive value of dopamine transporter SPECT imaging with [123I]PE2I in patients with subtle parkinsonian symptoms
    Morten Ziebell
    Birgitte B. Andersen
    Gerda Thomsen
    Lars H. Pinborg
    Merete Karlsborg
    Steen G. Hasselbalch
    Gitte M. Knudsen
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39 : 242 - 250
  • [50] Synthesis, enantiomeric resolution, and selective C-11 methylation of a highly selective radioligand for imaging the norepinephrine transporter with positron emission tomography
    Lin, KS
    Ding, YS
    [J]. CHIRALITY, 2004, 16 (07) : 475 - 481